Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06505421 · ClinicalTrials.gov registry record

Eccentric Exercise and Fatigue in Multiple Sclerosis

A clinical trial of Multiple Sclerosis and Fatigue, sponsored by Hunter College of City University of New York.

Recruiting
Registry status
30
Enrollment target
1
Study location

NCT06505421: Recruiting study of Multiple Sclerosis and Fatigue, sponsored by Hunter College of City University of New York.

NCT06505421 is a study of Multiple Sclerosis and Fatigue that is actively recruiting participants, run by Hunter College of City University of New York. The registered enrollment target is 30 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06505421, a study of Multiple Sclerosis and Fatigue, is actively recruiting participants, sponsored by Hunter College of City University of New York.

RECRUITING
Registry status
30 participants
Enrollment target
1
Study location

Study Summary

The goal of this observational study is to compare the impact of eccentric resistance training to traditional resistance training on fatigue in persons with multiple sclerosis (MS). The primary question this study is asking is the following: is eccentric resistance training more fatiguing than traditional resistance training in persons with MS?. Participants will be asked to come for two sessions for two weeks. In the first week, subjects will undergo a bout of either traditional or eccentric resistance training. The next day they will return to assess their level of fatigue. The following week the subject will return and undergo whatever type of training they did not experience the first week, and it's effects on fatigue will again be assessed. The difference between the subjects level of fatigue for either condition will be compared.

Primary Outcome

Subject walks at best possible pace with or without assistive device for 6 minutes. Total distance walked as well as distance per minute is measured

Interventions

  • BEHAVIORAL Resistance training

Study Locations (1)

New York

  • Hunter College, Physical Therapy Department, City University of New York - New York

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-07-01
Est. Completion 2026-12-30

What NCT06505421 shows while recruiting

NCT06505421 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (95% lower).

The record links to 2 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Resistance training is the first listed.

NCT06505421 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT06505421 about?

NCT06505421 is a clinical study titled "Eccentric Exercise and Fatigue in Multiple Sclerosis". The goal of this observational study is to compare the impact of eccentric resistance training to traditional resistance training on fatigue in persons with multiple sclerosis (MS). The primary question this study is asking is the following: is eccentric resistance training more fatiguing than tradi...

What is the current status of trial NCT06505421?

This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2024-07-01. Estimated completion is 2026-12-30.

What conditions does trial NCT06505421 study?

This clinical trial studies the following conditions: Multiple Sclerosis, Fatigue.

What interventions are being tested in trial NCT06505421?

The interventions under investigation include: Resistance training (BEHAVIORAL).

Who is sponsoring clinical trial NCT06505421?

This trial is sponsored by Hunter College of City University of New York, which has 29 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06505421 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06505421's enrollment target sits among peer trials

30 222nd of 315 higher than 76 of 315 other Multiple Sclerosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06505421, the US trial registry maintained by the National Library of Medicine. NCT06505421 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.